Johns Hopkins Drug Discovery - John Hopkins University
The Johns Hopkins Drug Discovery Program continues to work with the researchers across Johns Hopkins to research and develop tomorrow’s therapeutics for a wide range of human disorders.
Johns Hopkins, Drug Discovery, Transforming academic translational research
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-2,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-7.7,wpb-js-composer js-comp-ver-4.12.1,vc_responsive
Johns Hopkins University Drug Discovery

Transforming academic
translational research


Expertise in drug
discovery research


Developing for the future

What’s New?

JHDD start-up Lorem Therapeutics gets funding from IP Group

Click here to read more

JHDD receives $40.5 million to develop Glutamine Antagonists

Click here to read more

JHDD receives 3 TEDCO Maryland Innovation Initiative Awards
-Developing an inhibitor of neutral sphinghomyelinase2 for the treatment of Alzheimer’s disease

-Developing a therapeutic to prevent kidney toxicity in prostate cancer patients receiving PSMA-targeted radiotherapy

-Develop a potent drug with a novel mechanism for the treatment of leukemia and lymphoma

Click here to read more

Building innovative partnerships

Johns Hopkins University Drug Discovery - JHU Drug Discovery

Our HTS collaboration with Eisai and partnership with IOCB represent innovative ways to create a great synergy of complimentary organizations working together to develop new therapeutics.

Interested in Working With Us?

We welcome opportunities to discuss how we can work together in various capacities including laboratory services, drug discovery collaborations, and industrial collaborations.

Login to iLab to submit a proposal to JHDD.